ERBB2 and breast carcinoma: For patients with HR‐positive/HER2‐negative advanced breast cancer who previously underwent endocrine therapy, the SOLAR‐1 study assessed the efficacy and safety of combining fulvestrant with alpelisib versus fulvestrant and placebo.